Ten effects of testosterone treatment unfold on ten different schedules, from a few days to at least three years. At Longevity Benchmark, we look at published trial timelines before clinic marketing. A systematic review by Saad and colleagues in the European Journal of Endocrinology brought those schedules together, effect by effect. The trials measured testosterone replacement therapy (TRT) in men with a diagnosed deficiency.

The Verdict

Expect libido first, at around 3 weeks, plateauing at 6 weeks. Expect mood to follow, detectable at 3 to 6 weeks and maximal somewhere between 18 and 30 weeks. Expect body composition at 12 to 16 weeks and erections at up to 6 months. That lag behind desire is why men conclude too early that treatment has not worked. Hematocrit peaks at 9 to 12 months. The first year of monitoring is built around that peak. Bone density had not finished changing at 3 years. Judge the therapy against the measure you actually care about, on that measure's own schedule.

The Published Timeline, Effect by Effect

Ten effects of testosterone treatment have documented onset and maximum-effect windows, and no two of them match. The table below quotes the time spans reported by Saad and colleagues. Onset means the point at which a change first became detectable, and maximum means the point past which the review found no further gain.

EffectOnsetMaximum effectWhat this means in practice
Insulin sensitivity A few days Glycemic control only after 3 to 12 months The fastest measurable change, and the one patients notice least
Sexual interest 3 weeks Plateaus at 6 weeks No further gain is expected after week 6
Quality of life 3 to 4 weeks Longer than the onset Onset is early, the ceiling is not well pinned down
Depressive mood 3 to 6 weeks 18 to 30 weeks The gap between first change and full effect is the widest of any mood measure
Inflammation markers 3 to 12 weeks Within the same window Measured on labs rather than felt
Lipids 4 weeks 6 to 12 months Direction of change depends on the lipid fraction
Body composition 12 to 16 weeks Stabilizes at 6 to 12 months Can keep moving slightly for years after it stabilizes
Erythropoiesis (red cell production) 3 months Peaks at 9 to 12 months The reason hematocrit is rechecked through the first year
Erections and ejaculation Up to 6 months Up to 6 months The slowest sexual measure, and months behind libido
Bone mineral density 6 months Still rising at 3 years The only measure that had not finished changing when the review closed

A man starts treatment, notices his libido lift in the first month, and reads that as proof the therapy works. He then waits for everything else on the same schedule and nothing arrives. Bone, blood and body composition were never going to move on a four-week clock.

Why Libido Takes Three Weeks and Bone Takes Three Years

The spread in the timeline reflects how long each tissue takes to change rather than how strongly testosterone acts on it. Sexual interest is a signaling effect in the brain, so it changes about as fast as the hormone level does. Bone is remodeled by cells that resorb and rebuild it over months, and a density scan cannot see a change until enough of that cycle has run.

Red cell production sits between the two. The marrow responds over weeks, and the review put the peak at 9 to 12 months. That curve is slow. A normal hematocrit at three months says very little about where the number lands at month ten. Each interval is set by how fast that tissue changes, which is why the monitoring schedule looks the way it does.

What the Preparation Changes About the Blood Level

The preparation changes the shape of your blood level between doses and leaves the effect timeline broadly intact. An intramuscular ester and a daily gel put testosterone into circulation on very different rhythms, and the downstream effects still run on the schedules in the table above.

PreparationHow the blood level behavesWhat that changes for you
Testosterone cypionate or enanthate (intramuscular) Days to a peak, then a decline across the dosing interval Blood levels swing between injections, so how you feel can track the swing rather than the therapy
Testosterone undecanoate (long-acting intramuscular) Weeks to a steadier level Fewer peaks and troughs, and a longer wait before the level reflects a change
Transdermal gel or solution Hours to a daily peak, cleared daily Daily application, and a missed day shows up quickly in the level

The preparation does change how a swing feels. On a long dosing interval, some men report a difference between the days after an injection and the days before the next one. That is a level effect rather than a signal that the therapy has stopped working. Swing is also why prescribers revisit the interval. A trough level drawn just before the next dose tells a prescriber more than a random draw does.

Early Adjustment Symptoms and Biological Adaptation Timelines

Early complaints of fatigue or malaise during the initial weeks of testosterone replacement therapy conflict with the biological timeline documented in clinical trials. Popular discussions frequently blame an acute estradiol surge, yet routine monitoring of estradiol is not recommended during testosterone therapy (a review of testosterone-associated erythrocytosis). Estradiol produced through aromatisation contributes to testosterone-associated erythrocytosis, but that physical process takes months to alter blood counts.

Testosterone therapy stimulates erythropoiesis and raises haematocrit, with erythrocytosis risk close to fourfold greater than placebo (a review of erythrocytosis following testosterone therapy). The route changes the curve. With transdermal formulations, haemoglobin and haematocrit rise over roughly the first five to six months and then plateau, earlier than the 9-to-12-month peak this page describes for red cell production overall. Time to exceed a 50 percent haematocrit averages 10.5 ± 9.1 months for injections, 14.0 ± 12.6 months for transdermal gels, and 16.4 ± 10.7 months for subcutaneous pellets.

Delivery routes change haematocrit risk considerably. Short-acting injectable testosterone produces a 66.7 percent erythrocytosis rate, compared to 35.1 percent for subcutaneous pellets, 12.8 percent for transdermal gels, and 7 percent for extended-release testosterone undecanoate (the same review). Across all formulations, the pooled mean haematocrit increase does not exceed 4.3 percentage points, as compared in TRT injections vs cream vs pellets (the erythrocytosis review).

Thromboembolic risk follows a distinct early window. Venous thromboembolism risk appears concentrated in the early months after initiation, even though substantial red cell mass accumulation takes longer. The Endocrine Society treats a baseline haematocrit above 50 percent as a relative contraindication to starting therapy, and a value above 54 percent as a reason to stop (the same review).

An alternative published monitoring schedule checks blood counts at three to four months, at one year, and then annually. The measured markers move on a months-long clock, not a two-week one. Our pages on TRT side effects and risks and high haematocrit on TRT cover what each one catches.

When Six Weeks Passes and Nothing Has Changed

Six weeks is the first point at which the published timeline stops offering an explanation. Sexual interest should have plateaued by then and depressive mood should at least have started to move. If neither has, the timeline has been exhausted for those two measures, though it has barely begun for body composition, blood and bone.

Three explanations account for most of these cases.

  • The dose has not brought the blood level into the target range, which a trough measurement answers directly.
  • The symptoms were not driven by testosterone. Fatigue, low mood and low libido have a long list of other causes.
  • Another condition is contributing, including thyroid disease, sleep apnea and depression.

Our guides to the signs of low testosterone and the thyroid panel cover the overlap, and home sleep apnea testing covers the third. Each is a question for the clinician holding your labs.

Who Should Not Use This Timeline

This timeline describes men receiving treatment for diagnosed hypogonadism, and it does not transfer to three groups. Men with testosterone in the normal range have no deficiency for these numbers to correct, and the review studied correction of a deficiency. Men taking testosterone for athletic performance are using doses and goals outside what these trials measured, so nothing here predicts their experience. Men trying to conceive should know that exogenous testosterone suppresses sperm production, a separate matter from the timeline above and covered in our guide to TRT and fertility.

Anyone in the first group is better served by identifying what else explains the symptoms before starting a therapy that has its own monitoring burden. Enclomiphene compared with TRT covers one alternative route that preserves fertility.

What Would Change Our Reading of the Timeline

Three findings would move these numbers.

  • A trial showing that onset varies by preparation would undercut the central point above. The current review reports the time-course by effect rather than by ester.
  • A longer follow-up on bone density would close the open end of that row, which still reads "at least three years" because the studies stopped rather than because the effect did.
  • New long-term data on any single measure would revise that row without disturbing the rest, because each row rests on its own body of evidence. The review dates from 2011, and several large trials have reported since, including cardiovascular safety data.

Check the current Endocrine Society testosterone guideline for the monitoring intervals in force when you start.

Before starting, write down the one measure you most want changed and find its row in the table. Find that row before month one, and the first six months stop reading as a failure.

Frequently Asked Questions

How long does TRT take to work?

It depends entirely on which effect you mean, and the spread is wide. In the systematic review by Saad and colleagues in the European Journal of Endocrinology, sexual interest appeared after 3 weeks and plateaued at 6 weeks. Erections and ejaculation could take up to 6 months. Body composition changed at 12 to 16 weeks and stabilized at 6 to 12 months. Bone mineral density was detectable after 6 months and was still improving at 3 years. Name the effect first. Without it, any single answer is wrong for most of the list.

Why is hematocrit rechecked so often in the first year?

Red cell production responds to testosterone at about 3 months and peaks at 9 to 12 months, so the first year is when the number moves most. Raised hematocrit is a common laboratory finding on testosterone therapy, and the monitoring interval exists because the peak sits inside the first year rather than at the start. The Endocrine Society publishes the monitoring schedule its guideline recommends. Your prescriber sets that schedule against your own baseline rather than against a general timeline.

Nothing has changed at 6 weeks. Is that normal?

Six weeks is long enough to have expected a change in sexual interest and mood, and not long enough for most other measures. Saad and colleagues put the libido plateau at 6 weeks and depressive mood at 3 to 6 weeks for onset. So a complete absence of change in those two by week 6 is the point at which the published timeline stops explaining it. Several other things can: the dose has not brought the level into range, the symptoms were not driven by testosterone in the first place, or something else is contributing. All three are questions for the prescriber who ordered the labs, and all three are answered with a blood test rather than a longer wait.

Why do erections lag months behind libido?

Erections are the slowest sexual measure in the review, listed at up to 6 months, while sexual interest plateaus at 6 weeks. Desire returns early enough that the delay in erectile response reads as a failure of the therapy. It is not. That gap also means erectile function is a poor early read on whether treatment is working. Erectile difficulty has vascular and neurological causes that testosterone does not address, so an unchanged result at 6 months is a reason for a wider workup.

How long does testosterone cypionate take to work?

Cypionate reaches a peak blood level within days of an injection and then declines across the dosing interval, but the clinical effects follow the timeline above rather than the injection schedule. A man on cypionate and a man on a gel should expect libido to respond on roughly the same three-week schedule, because the review reported the time-course by effect rather than by preparation. The ester changes the shape of the blood level between doses. Some men on longer intervals report feeling different at the end of a cycle than at the start.

How long does testosterone gel take to work?

A transdermal gel raises blood testosterone within hours of the first application and clears on a daily cycle, so a missed day is visible in the level. The downstream effects still run on the published schedule: about 3 weeks for sexual interest, 12 to 16 weeks for body composition, 6 months before bone density moves. The daily rhythm is the practical difference. Gels also carry a transfer risk to partners and children through skin contact, which the US Food and Drug Administration (FDA) has issued specific guidance on.

Does a higher dose make TRT work faster?

The published time-course is not a dose-response curve, and the review did not find that raising the dose compressed the schedule. Bone density was still rising at 3 years in the review, and red cell production peaked at 9 to 12 months. A higher dose reliably raises the rate of the dose-related findings, including hematocrit. That is why the timeline is worth knowing before starting: it sets an expectation that removes the main reason men ask for an increase in the first three months.

Related